Elicio Therapeutics Inc. Common Stock (ELTX)
Stock · NASDAQ · Health Care
$2.84as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$3.09
Industry
Biotechnology: Pharmaceutical Preparations
About ELTX
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide trea…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 33
- Website
- elicio.com/
Fundamentals
- 1-day range
- $2.84$3
- Market cap
- $65.84M
- P/E (trailing)
- —
- P/E (forward)
- -1.31
- EPS (trailing)
- $-2.41
- Dividend yield
- —
- Beta
- 1.30
- Avg. volume
- 1.73M
52-week range
$2.66$16
Forecasts
2 analyst ratings
Buy 80%
Hold 20%
Sell 0%
1-year price forecast
High
$23
+709.9%
Median
$16.5
+481.0%
Low
$10
+252.1%
Elicio Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ELTXElicio Therapeutics Inc. Common Stock$2.86▼ 4.67%Market cap $65.84MP/E —$2.66$16
- MNOVMedicinova Inc Common Stock$1.44▲ 1.05%Market cap $65.46MP/E —$1.17$1.96
- SPROSpero Therapeutics Inc. Common Stock$1.2▼ 0.83%Market cap $66.59MP/E 4.73$1.08$3.08
- CINGCingulate Inc. Common Stock$5.32▼ 2.21%Market cap $65.06MP/E —$3.16$11.89
- ACRVAcrivon Therapeutics Inc. Common Stock$2.06▼ 4.19%Market cap $66.77MP/E —$1.27$3.56
- PLRXPliant Therapeutics Inc. Common Stock$1.11▼ 3.48%Market cap $64.40MP/E —$1.02$1.95
- RNTXRein Therapeutics Inc. Common Stock$0.7621▼ 2.67%Market cap $63.77MP/E —$0.694$2.18
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ELTX Elicio Therapeutics Inc. Common Stock | $65.84M | — | $2.86 | ▼ 4.67% | $2.66$16 |
| MNOV Medicinova Inc Common Stock | $65.46M | — | $1.44 | ▲ 1.05% | $1.17$1.96 |
| SPRO Spero Therapeutics Inc. Common Stock | $66.59M | 4.73 | $1.2 | ▼ 0.83% | $1.08$3.08 |
| CING Cingulate Inc. Common Stock | $65.06M | — | $5.32 | ▼ 2.21% | $3.16$11.89 |
| ACRV Acrivon Therapeutics Inc. Common Stock | $66.77M | — | $2.06 | ▼ 4.19% | $1.27$3.56 |
| PLRX Pliant Therapeutics Inc. Common Stock | $64.40M | — | $1.11 | ▼ 3.48% | $1.02$1.95 |
| RNTX Rein Therapeutics Inc. Common Stock | $63.77M | — | $0.7621 | ▼ 2.67% | $0.694$2.18 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Targetbenzinga · 8/18/2026
- HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price TargetBenzinga · 8/18/2026
- Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesYahoo · 8/13/2026
- Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) EstimateBenzinga · 8/13/2026
Insider Activity
Insider Actions →Acquired
365.3K
Disposed
0
- Peter DeMuth · July 16, 2026 · Grant52.8K
- Robert Connelly · July 16, 2026 · Grant186.9K
- Preetam Shah · July 16, 2026 · Grant60.8K
- Christopher Haqq · July 16, 2026 · Grant64.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 3.06M
- Total value held
- $32.47M
- Institutional holders
- 47
Top holders this quarter
- Unknown630.9K
- Unknown518.6K
- Unknown373.8K
- Unknown244.8K
- Unknown135.2K
- Unknown121.6K
- Unknown115.6K
- Unknown92.8K
- Unknown78.1K
- Unknown74.5K
See the full, filterable feed with live charts on the MarketWall dashboard.